Document is current

Article History

Received: 4 August 2022

Revised: 12 December 2022

Accepted: 13 December 2022

First Online: 24 December 2022

Declarations

:

: S Gholizadeh is an employee of Genentech, Inc., and shareholder of F. Hoffmann-La Roche Ltd. A Exuzides was an employee of Genentech, Inc., at the time of this study and manuscript preparation and is a shareholder of F. Hoffmann-La Roche Ltd. KE Lewis, C Palmer, M Waltz, and AM Jolley declare that they have nothing to disclose. JW Rose has received research support from the National Multiple Sclerosis Society, Guthy-Jackson Charitable Foundation, National Institutes of Health (NIH), Friends of MS and Biogen. He has received intellectual property interests from a discovery or technology relating to health care. JM Behne has received personal compensation as Executive Director of the Guthy-Jackson Charitable Foundation. MK Behne has received personal compensation for serving as an independent contractor with the Guthy-Jackson Charitable Foundation. TF Blaschke has received personal compensation for serving as a consultant for Merck, the Guthy-Jackson Charitable Foundation, and the Bill and Melinda Gates Foundation. He has received personal compensation for serving as an officer or member of the board of directors for Durect. He has received personal compensation for serving as an editor, associate editor, or editorial advisory board member for Annual Reviews. He has received stock or ownership interest from Durect. He has received research support from the Bill and Melinda Gates Foundation. TJ Smith has received personal compensation as an advisor to the Guthy-Jackson Charitable Foundation. He has received personal compensation for serving as a consultant for Horizon and Immunovant. He has received personal compensation for serving on a scientific advisory or data safety monitoring board for Horizon. He has received intellectual property interests from discoveries and technologies relating to health care. J Sinnott has received research support from the Guthy-Jackson Charitable Foundation and the NIH. LJ Cook has received research support from the Centers for Disease Control and Prevention, Guthy-Jackson Charitable Foundation, Utah Highway Safety Office and NIH. MR Yeaman has received personal compensation as an advisor to the Guthy-Jackson Charitable Foundation. He has received personal compensation for serving on a scientific advisory board for Genentech. He has received honoraria from Roche, Horizon and Alexion for scientific presentations pertaining to NMOSD. He has received research support from the NIH (National Institute of Allergy and Infectious Disease) and the US Department of Defense. He holds numerous patents and has received intellectual property interests from discoveries and technologies relating to health care.

: Enrollment was conducted in accordance with guidelines specified by the Office of Human Research Protections of the FDA. A standardized protocol, manual of operations, patient study file, and informed consent or assent documents were approved by institutional review boards or respective clinical study sites.

: Written and verbal consent or assent was obtained before beginning the study procedures.